Compare · ALGS vs BIIB
ALGS vs BIIB
Side-by-side comparison of Aligos Therapeutics Inc. (ALGS) and Biogen Inc. (BIIB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALGS and BIIB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $29.52B, about 903.5x ALGS ($32.7M).
- Over the past year, ALGS is down 33.0% and BIIB is up 51.1% - BIIB leads by 84.1 points.
- BIIB has been more active in the news (20 items in the past 4 weeks vs 3 for ALGS).
- BIIB has more recent analyst coverage (25 ratings vs 15 for ALGS).
- Company
- Aligos Therapeutics Inc.
- Biogen Inc.
- Price
- $5.34+4.71%
- $199.92+2.89%
- Market cap
- $32.7M
- $29.52B
- 1M return
- -17.78%
- +0.26%
- 1Y return
- -33.00%
- +51.13%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 3
- 20
- Recent ratings
- 15
- 25
Aligos Therapeutics Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-Ã agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting SARS-CoV-2; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest ALGS
- Lake Street initiated coverage on Aligos Therapeutics with a new price target
- Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
- Cantor Fitzgerald initiated coverage on Aligos Therapeutics with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Aligos Therapeutics Inc.
- Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
- SEC Form 10-Q filed by Aligos Therapeutics Inc.
- Aligos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
- Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
- SEC Form DEFA14A filed by Aligos Therapeutics Inc.
Latest BIIB
- Director Hawkins William A was granted 1,505 shares, increasing direct ownership by 17% to 10,365 units (SEC Form 4)
- Director Sherwin Stephen A was granted 1,505 shares, increasing direct ownership by 11% to 15,193 units (SEC Form 4)
- Director Rowinsky Eric K was granted 1,505 shares, increasing direct ownership by 6% to 25,844 units (SEC Form 4)
- Director Mantas Jesus B was granted 1,505 shares, increasing direct ownership by 15% to 11,263 units (SEC Form 4)
- Director Langer Susan was granted 1,505 shares, increasing direct ownership by 29% to 6,634 units (SEC Form 4)
- Director Patolawala Monish D was granted 1,505 shares, increasing direct ownership by 41% to 5,215 units (SEC Form 4)
- Director Pangalos Menelas N converted options into 2,370 shares and was granted 1,505 shares (SEC Form 4)
- Director Minor Lloyd was granted 1,505 shares, increasing direct ownership by 64% to 3,875 units (SEC Form 4)
- Director Freire Maria C was granted 2,005 shares, increasing direct ownership by 29% to 8,820 units (SEC Form 4)
- Biogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders